NCT03232164CompletedEarly phase 1
PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
Source: ClinicalTrials.gov · Last updated 12 Dec 2024
Brief summary (registry, in English)
The overall goal of this research is to validate and develop a non-invasive imaging biomarker of prostate cancer detection, progression, and recurrence. Development of such a biomarker may be useful to differentiate indolent from aggressive prostate cancer phenotypes allowing for selection of an appropriate risk adaptive therapy.
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 126 (actual)
- First submitted
- 17 Jul 2017
- Start date
- 2 Feb 2017
- Primary completion date
- 1 Nov 2024
- Lead sponsor
- University of Wisconsin, Madison
- Diseases
- Prostate cancer
- NCT number
- NCT03232164
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 126
- From 2 Feb 2017 to the primary completion date, 1 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
This page is information, not medical advice. Discuss any trial with your doctor.